In-stent restenosis and stent thrombosis represent the main adverse reactions to coronary stents and individual
susceptibility appears to play an important role in their onset. In particular, inflammatory status, classically assessed by
C-reactive protein levels, predicts the risk of in-stent restenosis after bare-metal stent implantation but not after
drug-eluting stent (DES) implantation. On the other hand, C-reactive protein seems to predict the risk of stent thrombosis
after treatment with DES but not with bare-metal stent. If DES have considerably reduced, as compared to bare-metal
stent, the rate of adverse reaction in the first year after implantation, concern is emerging about late events that seem to be
related to delayed healing and allergic reactions to polymers, a process in which eosinophils play an important role by
enhancing restenosis and thrombosis.
Keywords: Drug-eluting stent, in-stent restenosis, stent thrombosis, inflammation, allergy, eosinophils.
Rights & PermissionsPrintExport